Evidence map›Paper›PMID 32090963›Full record

ArticlePlacenta2020

Nanoparticle mediated increased insulin-like growth factor 1 expression enhances human placenta syncytium function.

Rebecca L Wilson, Kathryn Owens, Emily K Sumser, Matthew V Fry, Kendal K Stephens, Marcel Chuecos, Maira Carrillo, Natalia Schlabritz-Loutsevitch, Helen N Jones

Open access · greenAbstract read
In one paragraph

Article in Placenta, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 48 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. A Review of Nanotechnology for Treating Dysfunctional Placenta.Frontiers in bioengineering and biotechnology · 2022
    Review
  20. Placental treatment withFrontiers in physiology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Rebecca L WilsonCenter for Fetal and Placental Research, Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, USA, 45229. Electronic address: Rebecca.Wilson@cchmc.org.
Kathryn OwensCenter for Fetal and Placental Research, Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, USA, 45229.
Emily K SumserCenter for Fetal and Placental Research, Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, USA, 45229.
Matthew V FryCenter for Fetal and Placental Research, Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, USA, 45229.
Kendal K StephensCenter for Fetal and Placental Research, Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, USA, 45229.
Marcel ChuecosTexas Tech University Health Sciences Center at the Permian Basin, Odessa, TX, USA, 79763.
Maira CarrilloTexas Tech University Health Sciences Center at the Permian Basin, Odessa, TX, USA, 79763.
Natalia Schlabritz-LoutsevitchTexas Tech University Health Sciences Center at the Permian Basin, Odessa, TX, USA, 79763.
Helen N JonesCenter for Fetal and Placental Research, Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, USA, 45229.
Cincinnati Children's Hospital Medical Center · USTexas Tech University Health Sciences Center · USChildren's Hospital & Medical Center · USTexas Tech University · US

Funding

Placental-specific therapy for fetal growth restrictionR01HD090657 · NICHD · UNIVERSITY OF FLORIDA · PI HELEN N JONES · 2017 to 2026
$2.6M
Insulin-like Growth Factor 1 Gene Therapy; Correction of Placental InsufficiencyR00HD068504 · NICHD · CINCINNATI CHILDRENS HOSP MED CTR · PI JONES, HELEN N · 2014 to 2016
$722k
Point-of-care monitoring of feto-placental oxygen uptakeR43HD095348 · NICHD · TOMOWAVE LABORATORIES, INC. · PI ORAEVSKY, ALEXANDER A · 2018 to 2018
$225k
NICHD NIH HHS R00 HD068504NICHD NIH HHS R01 HD090657NICHD NIH HHS R43 HD095348
6 · The paper itself

Abstract

introductionPlacental dysfunction is an underlying cause of many major obstetric diseases and treatment options for complications like fetal growth restriction (FGR) are limited .We previously demonstrated nanoparticle delivery of the human insulin-like growth factor 1 (hIGF1) transgene under control of the trophoblast-specific PLAC1 promoter maintains normal fetal growth in a surgically-induced FGR mouse model. However, uptake by human placental syncytiotrophoblast has yet to be determined.

methodsAn ex vivo human placenta perfusion model, term placenta villous fragments, and other in vitro syncytiotrophoblast models were used to determine nanoparticle uptake, transgene expression, and functional responses under oxidative stress conditions.

resultsIn the ex vivo perfusion, fluorescence from a Texas-Red conjugated nanoparticle increased in maternal perfusate upon nanoparticle addition and declined by the conclusion of the experiment (P < 0.001. Fluorescent histology confirmed localization in the syncytiotrophoblasts. No Texas-Red fluorescence was detected in the fetal perfusate. Transgene expression of hIGF1 in differentiated BeWo cells, isolated primary trophoblasts and fragments was increased compared to untreated (55,000-fold, P = 0.0003; 95-fold, P = 0.003; 400-fold, P < 0.001, respectively). Functionally, increased hIGF1 expression in villous fragments resulted in translocation of glucose transporter 1 to the syncytiotrophoblast cell membrane and under conditions of oxidative stress in BeWo cells, protected against increased cell death (P < 0.01) and decreased mitochondrial activity (P < 0.01).

conclusionThe current study confirms that our nanoparticle is capable of uptake in human placental syncytium which results in enhanced transgene expression, functional changes to cellular activity and protection against increased oxidative stress.

Indexed as

Gene Transfer TechniquesNanoparticlesAdultCell DifferentiationCells, CulturedDrug CarriersFemaleGene ExpressionGiant CellsHumansInfant, NewbornInsulin-Like Growth Factor IMalePlacentaPregnancyTransfectionDrug CarriersInsulin-Like Growth Factor IFetal growth restrictionInsulin-like growth factorNanoparticlePlacentaPlacental dysfunctionPregnancyTherapy

Identifiers

PMID32090963
PMCPMC7167609
OpenAlexW3006143370

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.